Intelligence Profile
Clinical Applications
ARA-290 (Cibinetide) is an erythropoietin-derived peptide that has been investigated across multiple therapeutic areas, with clinical research focused primarily on neurological conditions, metabolic disorders, and inflammatory diseases.
Primary Clinical Areas
Neurological Conditions
Clinical trials have explored ARA-290's potential in several neurological applications. A completed Phase 1/2 study (NCT02070783) examined cognitive and neural effects, while preclinical research demonstrates protective effects in cerebral ischemic stroke through β-common receptor pathways and potential applications in traumatic brain injury and peripheral nerve injury.
Metabolic Disorders
A Phase 2 trial (NCT01933529) investigated ARA-290's effects in prediabetes and type 2 diabetes, though the study status remains unknown. Additionally, a Phase 2 trial for diabetic macular edema was initiated but subsequently terminated (NCT06626971).
Inflammatory and Autoimmune Conditions
A completed Phase 2 study (NCT02039687) evaluated ARA-290's efficacy on corneal nerve fiber density and neuropathic symptoms in sarcoidosis patients, representing the most clinically advanced application with available completion data.
Mechanisms and Therapeutic Targets
Preclinical evidence suggests ARA-290 works through multiple pathways:
- Neuroprotection: Studies indicate protection against cisplatin-induced nephrotoxicity through modulation of apoptosis and inflammation pathways
- Cardiovascular effects: Research shows potential for reducing cardiac inflammation and attenuating age-related declines in heart function
- Bone health: Evidence demonstrates inhibition of osteoclastogenesis and increased bone mineral density in preclinical models
- Renal protection: Studies suggest benefits in hemolytic-uremic syndrome through innate repair receptor mechanisms
Current Clinical Status
The clinical development of ARA-290 appears limited, with only one definitively completed trial in sarcoidosis patients. The termination of the diabetic macular edema trial and unknown status of the diabetes study suggest challenges in clinical translation, despite promising preclinical findings across multiple organ systems.
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Consult healthcare professionals for treatment decisions.